Cook Medical Gets FDA Approval for Zilver PTX Drug Eluting Stent for the Treatment of Peripheral Arterial Disease (PAD)
Posted Nov 15 2012 11:42pm
The FDA has approved Cook Medical’s Zilver® PTX®, the first drug-eluting stent (DES) for treating peripheral arterial disease (PAD) in the above-the-knee femoropopliteal arteries. This is a new approach to treating PAD, and Cook Medical is the only manufacturer with a drug-eluting stent that has been shown to inhibit re-narrowing of arteries in the SFA by 50 percent. The key differentiator is the drug paclitaxel. This new treatment is going to change the way physicians treat PAD.
The stent has been approved in Europe already. In addition another article of interest was an interview I did a while back with UCLA Dr. Peter F. Lawrence, Director of the UCLA Gonda Vascular Center who treats patients for PAD. BD
Also a while back I spoke with Rob Lyles at Cook Medical where we talked about PAD the at the time the up and coming Zilver stent. These have to be a bit more rugged as the leg moves versus a stationary muscle like the heart for example.
I did this interview way back when the Medical Quack was still fairly new and updates on the Zilver stent as they came along and I am guessing this is about 3 years worth of writing about the stent until the FDA approval was given today. It makes you stop and think of all the time and expense needed today to bring a well needed product to market. BD